- BioVector NTCC典型培養物保藏中心
- 聯系人:Dr.Xu, Biovector NTCC Inc.
電話:400-800-2947 工作QQ:1843439339 (微信同號)
郵件:Biovector@163.com
手機:18901268599
地址:北京
- 已注冊
BA/F3_TFG-NTRK1激酶Kinase穩定表達細胞株-BioVector NTCC保藏中心
I. Introduction
Cell Line Name:
BA/F3_TFG-NTRK1
Gene Synonyms:
TRK-fused gene ,HMSNP, SPG57, TF6, TRKT3;neurotrophic receptor tyrosine kinase 1 ,MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA
Host Cell:
Ba/F3
Stability: 16 passages
Application:
Anti-proliferation assay and PD assay
Freeze Medium:
90% FBS+10% DMSO
Complete Culture Medium:
RPMI-1640+10%FBS+1 ug/ml puromycin
Mycoplasma Status:
Negative
II.Background
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).
a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).
b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).
c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)
III. Representative Data
1. Anti-proliferation assay
Figure 1. Anti-proliferation assay of two reference compounds on the BA/F3_TFG-NTRK1 Stable Cell Line
IV. Thawing
Thawing: Protocol
1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
4. Resuspend the cells in complete growth medium.
5. Add 10 ml of the cell suspension in a 10 cm dish.
6. Add promycin to a concentration of 1 μg/ml the following day.
Kinase細胞株
現代新藥研發的關鍵首先是尋找,確定和制備藥物作用靶點。在500多個已發現的藥物靶點里中,GPCR,Ion Channel,Kinase使用的最為廣泛。
激酶(kinase)是一類從高能供體分子(如ATP)轉移磷酸基團到特定靶分子(底物)的酶;這一過程謂之磷酸化。許多腫瘤的發生是由某些與生長相關的“激酶”發生突變導致異常活化引起的,因而針對這些突變激酶的抑制劑能夠有效抑制這些激酶的活性,從而達到抑制癌細胞增長的目的。
BioVector NTCC質粒載體菌種細胞蛋白抗體基因保藏中心
電話:+86-010-53513060
網址:www.biovector.net
I. Introduction
Cell Line Name:
BA/F3_TFG-NTRK1
Gene Synonyms:
TRK-fused gene ,HMSNP, SPG57, TF6, TRKT3;neurotrophic receptor tyrosine kinase 1 ,MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA
Host Cell:
Ba/F3
Stability: 16 passages
Application:
Anti-proliferation assay and PD assay
Freeze Medium:
90% FBS+10% DMSO
Complete Culture Medium:
RPMI-1640+10%FBS+1 ug/ml puromycin
Mycoplasma Status:
Negative
II.Background
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).
a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).
b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).
c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)
III. Representative Data
1. Anti-proliferation assay
Figure 1. Anti-proliferation assay of two reference compounds on the BA/F3_TFG-NTRK1 Stable Cell Line
IV. Thawing
Thawing: Protocol
1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
4. Resuspend the cells in complete growth medium.
5. Add 10 ml of the cell suspension in a 10 cm dish.
6. Add promycin to a concentration of 1 μg/ml the following day.
Kinase細胞株
現代新藥研發的關鍵首先是尋找,確定和制備藥物作用靶點。在500多個已發現的藥物靶點里中,GPCR,Ion Channel,Kinase使用的最為廣泛。
激酶(kinase)是一類從高能供體分子(如ATP)轉移磷酸基團到特定靶分子(底物)的酶;這一過程謂之磷酸化。許多腫瘤的發生是由某些與生長相關的“激酶”發生突變導致異常活化引起的,因而針對這些突變激酶的抑制劑能夠有效抑制這些激酶的活性,從而達到抑制癌細胞增長的目的。
BioVector NTCC質粒載體菌種細胞蛋白抗體基因保藏中心
電話:+86-010-53513060
網址:www.biovector.net
您正在向 biovector.net 發送關于產品 BA/F3_TFG-NTRK1激酶Kinase穩定表達細胞株-BioVector NTCC保藏中心 的詢問
- 公告/新聞